- In April 2023, Inspire Medical Systems, Inc., a pioneer in hypoglossal nerve stimulation therapy, announced the expansion of its therapy access program across multiple regions in Europe and Asia-Pacific, aiming to increase patient access to implant-based treatments for obstructive sleep apnea (OSA). The initiative includes partnerships with regional healthcare providers and training programs for surgeons, reinforcing Inspire’s commitment to global accessibility and addressing the growing demand for alternatives to CPAP therapy.
- In March 2023, Nyxoah SA, a Belgium-based medical device company, received expanded CE Mark approval for its Genio® bilateral hypoglossal nerve stimulation system, allowing broader patient eligibility in the European market. This regulatory milestone enables the company to reach more OSA patients and affirms the safety and efficacy of bilateral stimulation technology, positioning Genio as a next-generation solution in implantable sleep apnea therapies
- In March 2023, LivaNova PLC announced positive preliminary results from its OSCAR trial, which evaluates the effectiveness of its implantable phrenic nerve stimulation device for central sleep apnea (CSA). Conducted in collaboration with leading cardiac and sleep centers, the trial demonstrated promising efficacy and patient tolerance, highlighting LivaNova’s commitment to addressing the unmet clinical needs in CSA treatment
- In February 2023, Fisher & Paykel Healthcare entered into a strategic agreement with a major academic medical center in New Zealand to co-develop next-generation sleep apnea monitoring and implant integration technologies. This partnership aims to combine diagnostic precision with implant-based therapeutic delivery, supporting a more personalized and data-driven approach to sleep apnea management
- In January 2023, Respicardia, Inc., a subsidiary of Zoll Medical Corporation, launched a clinician training initiative across the United States to expand awareness and surgical expertise in implanting its Remedē System, a fully implantable device for treating CSA. The training program is designed to increase the availability of therapy and accelerate adoption among sleep specialists and cardiologists, reflecting the company’s mission to advance implant-based solutions for underserved sleep apnea patients
